FindTrial
Sign In

Senling Baizhu san on serum Nrf2 and Drp1 in patients with sarcopenia and its effect

The mechanism of SenlingBaizhu san in treating sarcopenia was studied based on Nrf2 and Drp1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072429
Enrollment
Unknown
Registered
2023-06-13
Start date
2023-06-19
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

Experimental group:Routine therapy + Senling Baizhu san
Control group:Routine therapy

Sponsors

The Third people's Hospital of Hangzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: control group, observation group age 65-90 years old, independent walking abilitydecreased muscle strength (grip strength: <26kg for men, <18kg for women) and/or decreased physical function (stride speed <0.8m/s)in stable health.

Exclusion criteria

Exclusion criteria: A person unable to act independently Chronic cardiopulmonary insufficiency Patients with severe renal insufficiency (creatinine clearance <30 ml/min) and need to restrict protein intake Malignant tumor Those with impaired cognitive function Coronary heart disease unstable angina pectoris, acute myocardial infarction Suffering from severe neurological diseases Hip and knee pain, dysfunction Recent history of trauma, fracture or surgery.

Design outcomes

Primary

MeasureTime frame
Nrf2;Drp1;grip strength;walking speed;muscle mass index;—

Countries

China

Contacts

Public ContactWang Qin

The Third People's Hospital of Hangzhou

ajin2501@126.com+86 139 6800 6906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026